Alpha Tau Medical Ltd. (DRTSW) Stock Analysis

Company Overview

Alpha Tau Medical Ltd. operates as a clinical-stage oncology therapeutics company dedicated to the research, development, and commercialization of diffusing alpha-emitters radiation therapy, specifically targeting the treatment of solid cancers through its proprietary Alpha-DaRT technology which is currently undergoing clinical trials for various forms. The company functions within the healthcare sector, although specific industry classifications and sector designations are not disclosed in the available data, suggesting a specialized niche within the broader biotechnology landscape. In terms of scale, the company employs a workforce of 121 individuals, while specific figures for market capitalization and annual revenue are not currently available for public disclosure. The absence of reported market cap and revenue data in this snapshot indicates that the company is likely a pre-revenue or early-stage entity where traditional valuation metrics based on current sales performance have not yet been established or are not materializing, placing the firm in a growth phase where value is derived from pipeline potential rather than historical financial output.

Financial Health

The company reports a net income of $-42,627,000 over the trailing twelve months, with an EBITDA of $-41,056,000, while revenue and total revenue growth figures are not available for calculation. The significant gap between the reported net income loss and the EBITDA figure reveals a substantial cost structure burden, likely driven by high research and development expenses, non-recurring costs, or significant other operating expenses that reduce bottom-line profitability before interest and taxes. Free cash flow stands at $-19,703,876, indicating that the company is currently burning cash to fund its operations and clinical trial activities, which limits immediate financial flexibility but is typical for clinical-stage biotech firms investing heavily in product development. All three margin metrics—gross margin, operating margin, and profit margin—are reported at 0.0%, which indicates that the company has not yet generated positive gross profit or operating income, a common characteristic of entities in the clinical trial stage before commercial product launch. The company holds $73.13M in cash against $13.73M in debt, resulting in a debt-to-equity ratio of 17.80, which suggests a balance sheet that is highly liquid regarding cash reserves but leveraged relative to equity in the traditional sense, though the low absolute debt level mitigates immediate refinancing risk. The current ratio is reported at 7.45, a figure that indicates extremely strong short-term liquidity and the ability to cover current liabilities many times over, providing a significant buffer for ongoing operational expenditures. Return on equity is -61.0% and return on assets is -27.6%, metrics that reveal management is currently deploying capital to generate losses rather than profits, reflecting the early-stage nature of the business model where capital is consumed to advance clinical programs rather than returned to shareholders through earnings.

Valuation Assessment

Trailing P/E and forward P/E ratios are not available due to the company's lack of positive earnings, meaning these traditional valuation multiples cannot be calculated or compared to peers to gauge expected earnings trajectory. The price-to-book ratio is stated at 1.00, indicating that the market values the company's equity at a level equal to its book value, which often occurs for loss-making companies where the market assigns no significant premium to future growth prospects or intangible assets beyond their recorded net asset value. Price-to-sales and EV/EBITDA ratios are not available, as the absence of revenue and positive earnings prevents the calculation of these alternative valuation metrics that typically provide insight into relative value for high-growth or unprofitable firms. The 52-week high is $0.97 and the 52-week low is $0.85, meaning the stock trades within a narrow band near its historical range, suggesting limited recent price momentum or volatility compression relative to the broader market context. The beta value is 1.03, which indicates that the stock's price volatility is slightly higher than the broader market average, implying that price movements in Alpha Tau Medical Ltd. tend to mirror or slightly exceed the fluctuations of the overall market index.

Growth & Income

Revenue growth and earnings growth rates over the year-over-year period are not available, preventing a direct comparison of whether earnings are growing faster or slower than revenue, though the lack of revenue data implies the company has not yet reached a stage of consistent commercial scaling. Since the company does not pay a dividend, there is no dividend yield or payout ratio to evaluate for sustainability, confirming that the firm retains all available cash flow to reinvest into research, development, and clinical trials rather than distributing income to shareholders. The overall growth and income profile is characterized by a complete absence of current commercial revenue or dividend income, with the company relying entirely on its cash reserves and potential future commercialization of its Alpha-DaRT technology to fund operations and achieve profitability in the future.